Family · Pharmaceutical analytical standards
Linagliptin
A DPP-4 inhibitor (gliptin) for type 2 diabetes, approved in 2011. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Unlike the other gliptins it is eliminated mainly through the bile and gut, not the kidneys: no dose change is needed when kidney function is poor.
No product matches your search.
EDQM standards 7
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
